DSM-ファルマニヒは、同社の新しいCBD製剤CBtru®とEpidiolexを比較した世界初の調査結果を発表しました。
このフェーズI臨床試験では、CBtru®は現在のゴールドスタンダードと同等以上のバイオアベイラビリティを提供し、被験者間の変動が少なく、食事の影響を受けにくいことが示されました。この固形製剤の画期的な進歩により、CBDの投与方法がより便利になり、患者の体験が改善される可能性があります。
講演者：
このセッションは20分間です。
Discover how dsm-firmenich and ten23 health are transforming biologic formulation development through advanced excipient options.
Explore what newly published CBtru® pharmacokinetic data means for solid oral drug development—and why clinical evidence underpins meaningful innovation.
Discover how pharmaceutical quality management is advancing through proactive strategies that reduce risk, improve visibility, and support compliance.
Have an idea for a new project, a groundbreaking innovation, or a need for expert services? Let’s talk.
Don’t just take our word for it. Discover how our solutions can support your product development journey.
Customized blends of functional ingredients in one single, efficient premix.
Streamline your product development process and get to market faster.
From trade shows to conferences and other industry events, find out where you can meet us next.
Talking Nutrition, Health & Care
Explore new science, consumer insights, industry news and more in our latest articles.
Discover educational whitepapers, webinars, publications and technical information.
Request samples, place orders and view product documentation.